Arecor Therapeutics PLC Arecor AGM statement (3465M)
23 May 2022 - 04:00PM
UK Regulatory
TIDMAREC
RNS Number : 3465M
Arecor Therapeutics PLC
23 May 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
AGM STATEMENT
Building on strong foundations to deliver a transformational
year
Cambridge, UK, 23 May 2022: Arecor Therapeutics plc (AIM: AREC),
the biopharmaceutical group advancing today's therapies to enable
healthier lives, provides the following update ahead of its Annual
General Meeting, held today at 1.00 pm at the offices of Covington
& Burling LLP, 22 Bishopsgate, London EC2N 4BQ.
At the meeting, Andrew Richards, Non-Executive Chair, will make
the following statement:
"2021 was a truly transformational year for Arecor and the
Company has continued to make huge strides to continue this
trajectory of growth. During the year, our pipeline of proprietary
and partnered products received validation through both exceptional
clinical data and partnership progress. It is our vision to create
a sustainable biopharmaceutical company, by rejuvenating existing
therapeutic products to make them better, safer and more convenient
to use.
Our two lead clinical stage programmes are focused on improving
the lives of those living with diabetes. The impact that the
growing global number of diabetes patients is having on our
resources, health sector and lives cannot be underestimated. The
Phase I clinical trial data for both our lead product, AT247, an
ultra-rapid insulin and for our second product AT278, a
concentrated rapid insulin targeting patients who require higher
volumes of insulin, excelled our expectations. We believe that our
products will provide that key to unlock the future treatment
landscape for diabetes.
With our partnered portfolio continuing to attractive high
calibre pharmaceutical companies and strong support from our
shareholders following our successful IPO on the London Stock
Exchange last year, we believe that Arecor is well positioned to
both deliver on existing programmes and attract new and exciting
opportunities in the coming year to create long-term shareholder
value."
Further information about the AGM can be found in the investor
centre section of our website
https://arecor.com/investor-centre/shareholder-information/. To
register for the webinar, click here.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMATMRTMTTTBLT
(END) Dow Jones Newswires
May 23, 2022 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2023 to Mar 2024